

The Biovantage Technology Development Fund

Biovantage Inc. was created in 2010 as an Alberta Ingenuity Centre for Research and Commercialization. The mission of Biovantage Inc. (Biovantage) is to accelerate the development and commercialization of innovative Biomedical Engineering (BME) technologies that have a meaningful impact for the Alberta economy and society. In support of this mission, Biovantage has created a technology development fund to provide technical, management and financial support to early stage technology projects. Eligibility and general guidelines for the funding program are provided below.

Program Eligibility

Biovantage funds biomedical technology projects that have “market pull”: i.e., they provide a clear value proposition to the marketplace. Biovantage projects leverage the R&D knowledge, know-how and infrastructure in biomedical engineering in Alberta. Ideas come from 3 sources:

- ideas that flow out of the academic research activities at post-secondary institutions.
- early stage ideas developed either in whole or in part by industry, but require the knowledge and infrastructure at the University to make them happen.
- Inventive ideas that flow out of the clinical realm and that require technical knowledge and expertise to turn them into reality.

Biovantage has divided projects into two general groupings, depending on where they fit on the technology development timeline:

Project Type	Duration	Eligible Costs	Values
1. Initial concept and technology development up to disclosure of Intellectual Property (IP)	Up to two years	<ul style="list-style-type: none"> • Preliminary business case, feasibility & patentability analysis • Primarily for technical work 	Up to \$150K
2. Projects that primarily address proof of concept to make a technology ready and attractive for private investment.	Up to two years	<ul style="list-style-type: none"> ▪ business plan ▪ IP protection and management plan ▪ Prototype development and/or studies demonstrating efficacy in the applications of interest. ▪ Commercialization pathway development 	Up to \$300K <ul style="list-style-type: none"> • up to \$50K for business plan development • up to \$50K for IP protection

The lead applicant is unrestricted. However, at least one of the primary applicants needs to be a faculty member at a post-secondary institution in Alberta.



Biovantage Inc.
2500 University Drive NW.
Calgary, Alberta, Canada.
T2N 1N4.

Application Process

If you have a biomedical technology project in need of support, we would like to hear from you. This is Biovantage's first call for funding proposals. There is no deadline to enter into the Biovantage funding process. The first round of proposal review and funding is scheduled to be completed for May 31. For further information regarding the application process, please contact Biovantage's Technology Innovation Director:

Dr. Gerald Cole

403.210.8792 (office)

gcole@biovantage.com